Why Your First Licensing Deal Will Cost You More Than You Made

Licensing your technology to a larger company feels like a win. Someone hands you a check, you keep doing research, and the grown-ups handle the messy business of actually selling things. What's not to like?

Photo by Steve DiMatteo on Pexels.

Everything. Almost everything.

The first licensing deal most technical founders sign is less a business arrangement and more a slow-motion transfer of leverage, yours to theirs. Not because the other party is evil. Because you don't know what you're agreeing to yet, and they absolutely do.

The Royalty Rate That Sounds Reasonable

You negotiate a 3% royalty on net sales. Feels fair. Maybe even good, depending on the industry. Then you find out how the licensee defines "net sales", and it includes deductions for returns, distributor discounts, freight, insurance, currency conversion losses, and a handful of other line items that exist primarily to shrink the base number before your percentage ever touches it.

Real net sales figures routinely come in at 40-60% of gross revenue. Your 3% just became 1.5% in practice. Over a $10M product line, that's $150K instead of $300K, before you pay the lawyer who negotiated the deal.

If you didn't negotiate a minimum annual royalty floor, you also have no guarantee they'll actually sell anything. A company can license your technology, pay you nothing because they hit none of the sales thresholds, and simultaneously block you from licensing it to anyone who would sell it. Exclusivity without minimums is just a parking spot for your IP.

Milestone Payments Are Not What You Think

Most early-stage licenses include milestone payments, $50K at first commercial sale, $100K at $1M in revenue, that sort of thing. These feel like a safety net. They are not.

What happens when they miss a milestone? The contract probably gives them a cure period to pay a reduced "catch-up" fee instead. Or it lets them terminate and walk away, keeping any sublicenses they already granted. Or, and this is the one that stings, it lets them renegotiate terms under duress, when you've already told your university tech transfer office you have a deal and you desperately need this to close.

Milestones without teeth are just optimism in legal formatting.

Sublicensing Is Where Things Get Weird

You licensed to Company A. Company A, in turn, sublicenses your technology to Company B, a manufacturer in a jurisdiction you've never heard of. Now the product is being made. You're entitled to a percentage of what Company A receives from Company B, not a percentage of what Company B actually sells.

If Company A negotiated a flat fee for that sublicense? You get a slice of a flat fee. Meanwhile, Company B is moving product at scale and you have no direct visibility into any of it.

Some licensors negotiate audit rights. Most first-time founders don't use them, because auditing a Fortune 500 partner feels adversarial and expensive. It is both. Do it anyway, periodically, because underpayment in royalty accounting is genuinely common, not always intentional, but common.

The Deal Structure That Actually Protects You

Here's what a defensible early licensing deal looks like:

graph TD
    A[Field-of-Use Limitation] --> B[Minimum Annual Royalties]
    B --> C{Milestones Met?}
    C -- Yes --> D[Exclusivity Maintained]
    C -- No --> E[Reverts to Non-Exclusive]
    D --> F[Audit Rights Exercised Annually]
    E --> F

Field-of-use limitations mean you license Company A for medical devices only, not diagnostics, not consumer electronics, not anything else they might dream up later. This keeps your option value intact for other markets.

Milestones that revert exclusivity (rather than letting the licensee pay a small penalty to keep it) actually create consequences. Audit rights you contractually commit to exercising, put it in the agreement that you will audit at least once every two years, change the psychological dynamic entirely.

What You Should Actually Do Before You Sign

Hire a licensing attorney who specializes in your sector. Not a general IP attorney. Not the university's counsel (whose job is to close deals, not protect your upside). Someone whose entire practice is technology licensing and who has seen 200 royalty accounting disputes.

Yes, that costs money you probably don't have. It costs less than the deal you're about to sign.

Get comparable deal terms. AUTM publishes licensing survey data. Your tech transfer office, if you're still connected to one, has seen dozens of deals. Ask what similar technologies have commanded. Walk in knowing the range.

And slow down. The urgency you feel to close this deal, the pressure that makes you want to just sign so you can tell people you have a licensing agreement, is the single most expensive emotion in deep tech commercialization.

There is no second-place prize for getting the deal done fastest. There is, however, a very real penalty for getting it done wrong.